GRAIL, Inc. (NASDAQ:GRAL) Major Shareholder Sells $16,830,294.00 in Stock

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) major shareholder Chun R. Ding sold 339,800 shares of GRAIL stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $49.53, for a total value of $16,830,294.00. Following the completion of the sale, the insider owned 3,305,055 shares of the company's stock, valued at approximately $163,699,374.15. The trade was a 9.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

GRAIL Stock Down 1.6%

NASDAQ:GRAL traded down $0.75 on Thursday, hitting $46.81. The stock had a trading volume of 1,042,680 shares, compared to its average volume of 1,198,104. GRAIL, Inc. has a 52 week low of $12.33 and a 52 week high of $63.99. The business's fifty day moving average is $40.41 and its 200 day moving average is $32.39. The company has a market cap of $1.68 billion and a PE ratio of -0.77.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.03) by $0.93. GRAIL had a negative return on equity of 17.99% and a negative net margin of 1,464.53%. The company had revenue of $31.84 million for the quarter, compared to analysts' expectations of $35.80 million. Equities analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GRAL has been the topic of a number of research analyst reports. Canaccord Genuity Group increased their price target on GRAIL from $32.00 to $43.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Morgan Stanley increased their target price on shares of GRAIL from $16.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 18th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Rhumbline Advisers bought a new stake in shares of GRAIL during the fourth quarter worth about $456,000. New York State Common Retirement Fund bought a new stake in GRAIL during the 4th quarter worth approximately $59,000. Bank of New York Mellon Corp purchased a new stake in shares of GRAIL in the fourth quarter worth approximately $6,262,000. Oppenheimer & Co. Inc. purchased a new stake in shares of GRAIL in the fourth quarter worth approximately $190,000. Finally, US Bancorp DE bought a new position in shares of GRAIL in the fourth quarter valued at approximately $133,000.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.